Sangamo Therapeutics (SGMO) Receivables Refunds (2023 - 2025)
Sangamo Therapeutics (SGMO) has 3 years of Receivables Refunds data on record, last reported at $4.6 million in Q3 2025.
- For Q3 2025, Receivables Refunds changed N/A year-over-year to $4.6 million; the TTM value through Sep 2025 reached $4.6 million, changed N/A, while the annual FY2024 figure was $4.1 million, 29.52% up from the prior year.
- Receivables Refunds reached $4.6 million in Q3 2025 per SGMO's latest filing, roughly flat from $4.6 million in the prior quarter.
- Across five years, Receivables Refunds topped out at $4.6 million in Q2 2025 and bottomed at $3.1 million in Q4 2023.
- Average Receivables Refunds over 3 years is $4.1 million, with a median of $4.2 million recorded in 2025.
- The widest YoY moves for Receivables Refunds: up 29.52% in 2024, down 29.52% in 2024.
- A 3-year view of Receivables Refunds shows it stood at $3.1 million in 2023, then grew by 29.52% to $4.1 million in 2024, then increased by 13.02% to $4.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables Refunds were $4.6 million in Q3 2025, $4.6 million in Q2 2025, and $4.2 million in Q1 2025.